Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel‐ and lectin‐based proteomics analyses

Jayapalan, Jaime Jacqueline; Ng, Keng L.; Razack, Azad Hassan Abdul; Hashim, Onn Haji

doi:10.1002/elps.201100608

Cited by 32 publications

(26 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abundance of these proteins is not altered by SFN administration alone (present study). Interestingly, transthyretin and high-molecular weight kininogen were found to be significantly enhanced in the sera of patients with prostate cancer compared with those of benign prostatic hyperplasia (44). …”

Section: Discussionmentioning

confidence: 99%

Chemoprevention of Prostate Cancer by d,l-Sulforaphane Is Augmented by Pharmacological Inhibition of Autophagy

et al. 2013

View full text Add to dashboard Cite

There is preclinical evidence that oral administration of D,L-sulforaphane (SFN) can decrease the incidence or burden of early-stage prostate cancer (PIN) and well-differentiated cancer (WDC), but not late-stage poorly differentiated cancer (PDC). Because SFN treatment induces cytoprotective autophagy in cultured human prostate cancer cells, the present study tested the hypothesis that chemopreventive efficacy of SFN could be augmented by pharmacological inhibition of autophagy using chloroquine (CQ). Incidence of PDC characterized by prostate weight of >1g was significantly lower in the SFN+CQ group compared with control (P=0.004), CQ (P=0.026) or SFN group (P=0.002 by Fisher’s exact test). Average size of the metastatic lymph-node was lower by about 42% in the SFN+CQ group compared with control (P=0.043 by Wilcoxon test). On the other hand, the SFN+CQ combination was not superior to SFN alone with respect to inhibition of incidence or burden of microscopic PIN or WDC. SFN treatment caused in vivo autophagy as evidenced by transmission electron microscopy. Mechanistic studies showed that prevention of prostate cancer and metastasis by the SFN+CQ was associated with decreased cell proliferation, increased apoptosis, alterations in protein levels of autophagy regulators Atg5 and phospho-mTOR, and suppression of biochemical features of epithelial-mesenchymal transition. Plasma proteomics identified protein expression signature that may serve as biomarker of SFN+CQ exposure/response. This study offers a novel combination regimen for future clinical investigations for prevention of prostate cancer in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemoprevention of Prostate Cancer by d,l-Sulforaphane Is Augmented by Pharmacological Inhibition of Autophagy

et al. 2013

View full text Add to dashboard Cite

show abstract

“…They have been used to determine the cancer biomarkers in recent years [5]. Lectins are carbohydrate-binding proteins and play a key role in diverse biological applications [6,7].…”

Section: Introductionmentioning

confidence: 99%

Concanavalin A immobilized magnetic poly(glycidyl methacrylate) beads for prostate specific antigen binding

İdil

Perçin

Karakoç

et al. 2015

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

“…In addition, enrichment steps can also be performed to samples, to enable a study of a less complex subproteome. For (29)(30)(31)(32).…”

Section: Biomarker For Bone Tumors From Genomics and Proteomics Studiesmentioning

confidence: 99%

Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges

Wan-Ibrahim

Singh

Hashim

et al. 2015

Mol Med

Self Cite

View full text Add to dashboard Cite

Diagnosis of bone tumor currently relies on imaging and biopsy, and hence, the need to find less invasive ways for its accurate detection. More recently, numerous promising deoxyribonucleic acid (DNA) and protein biomarkers with significant prognostic, diagnostic and/or predictive abilities for various types of bone tumors have been identified from genomics and proteomics studies. This article reviewed the putative biomarkers for the more common types of bone tumors (that is, osteosarcoma, Ewing sarcoma, chondrosarcoma [malignant] and giant cell tumor [benign]) that were unveiled from the studies. The benefits and drawbacks of these biomarkers, as well as the technology platforms involved in the research, were also discussed. Challenges faced in the biomarker discovery studies and the problems in their translation from the bench to the clinical settings were also addressed.

show abstract

Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel‐ and lectin‐based proteomics analyses

Cited by 32 publications

References 37 publications

Chemoprevention of Prostate Cancer by d,l-Sulforaphane Is Augmented by Pharmacological Inhibition of Autophagy

Chemoprevention of Prostate Cancer by d,l-Sulforaphane Is Augmented by Pharmacological Inhibition of Autophagy

Concanavalin A immobilized magnetic poly(glycidyl methacrylate) beads for prostate specific antigen binding

Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges

Contact Info

Product

Resources

About